SEGOTX
Live / Allowed — Published for opposition (as of 14 Jul 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 19 Sept 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99402425
- Mark type
- Word mark
- Filed
- 19 Sept 2025
- Published for opposition
- 14 Jul 2026
- Attorney of record
- Jonathan H. Love
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in suppressing tumours; pharmaceutical preparations and substances for the treatment of oncological-related diseases and disorders; chemical preparations for pharmaceutical or medical purposes, namely for treating cancer; biological preparations for the treatment of cancer; small molecule pharmaceutical preparations for the treatment of cancer; small molecule pharmaceutical preparations for use in suppressing tumours; radiolabeled pharmaceutical preparations for the treatment of cancer; pharmaceutical preparation for use in suppressing tumours
- Class 009 — Scientific and electric apparatus: Downloadable drug discovery screening software for identifying and characterizing small molecule candidates for the treatment of cancer
- Class 042 — Scientific and technological services: Pharmaceutical research and development; pharmaceutical research and development services in the field of small molecule cancer therapeutics; scientific and technological services, namely, research and development in the field of cancer-related pharmaceuticals and cancer-related drug discovery; research and development of pharmaceutical preparations for treating cancer; providing online non-downloadable software platforms for screening, analyzing, and identifying potential drug candidates; providing online non-downloadable software platforms for screening, analyzing, and identifying potential drug candidates for treating cancer; pharmaceutical research services; testing, inspection, research, or development of pharmaceutical preparations for cancer; providing medical and scientific research information in the field of pharmaceuticals; research and development of pharmaceuticals for the treatment of cancer; laboratory research services relating to pharmaceuticals; laboratory research services relating to pharmaceuticals for treating cancer; consulting services in the field of pharmaceutical research and development; design and development of computer software for use in cancer-related pharmaceutical research, bioinformatics, and cancer-related drug discovery; drug discovery services; scientific and medical research services relating to radiolabeled small molecules for use in oncology; providing temporary use of a non-downloadable drug discovery screening software platform for identifying and characterizing small molecule candidates for the treatment of cancer.
- Class 044 — Medical, beauty and agricultural services: Medical diagnostic services; providing medical information in the field of pharmaceutical research and clinical trials; consulting services in the field of medical testing, diagnostics, and patient-specific therapies; providing medical information in the field of oncology, namely on radiolabeled small molecule diagnostics; consulting services in the field of medical care featuring medical testing and diagnostic screening for cancer.
- Class 045 — Legal and security services: Licensing of intellectual property
Owner
- SEGO THERAPEUTICS INC, Salt Lake City, UT, US
- SEGO THERAPEUTICS INC, Salt Lake City, UT, US
Prosecution history
- 14 Jul 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 14 Jul 2026 — PUBLISHED FOR OPPOSITION
- 08 Jul 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 17 Jun 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 12 May 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 12 May 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 12 May 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 12 Feb 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 12 Feb 2026 — NON-FINAL ACTION E-MAILED
- 12 Feb 2026 — NON-FINAL ACTION WRITTEN
- 11 Feb 2026 — ASSIGNED TO EXAMINER
- 10 Feb 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 19 Sept 2025 — APPLICATION FILING RECEIPT MAILED
- 19 Sept 2025 — NEW APPLICATION ENTERED